Partner with Karius to discover new biomarkers and develop assays that can help you select patients, predict response, enable early detection, and monitor disease progression and remission.
Our platform generates quantitative microbial signatures of bacteria, fungi, viruses and protozoa in plasma using next-generation sequencing of microbial cell–free DNA (mcfDNA).
Applications of mcfDNA Biomarkers:
- Potential selection of eligible subjects
- Rapid detection and monitoring of microbial load
- Monitoring drug efficacy
- Assisting with determination of dosing and duration of treatment
- Identification of co-infections that could impact therapeutic efficacy, safety, and adverse events
For more information or to discuss biomarker discovery and assay development in your clinical trials, please contact us at [email protected].
For publications visit www.kariusdx.com/clinical-evidence/clinical-data.
ll motivate the user to act, or to answer the call if you will. There can be a large amount of text here